Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AZD2389 in healthy participants
NCT06138795Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD2389 in metabolic dysfunction-associated steatohepatitis (MASH) and Liver Fibrosis (LF) (14 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AE) and serious adverse events (SAE). Started Nov 2023; status: completed.
02
Drugs
AZD2389
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT06138795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138795.